UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2007

Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)

Florida
  000-27836
  65-0643773
(State or other
jurisdiction of
incorporation) 		   (Commission
File Number) 		   (IRS Employer 
Identification No.)

2 Snunit Street
Science Park
POB 455
Carmiel, Israel 21000

(Address of principal executive offices) (Zip Code)

 

(Former Name or Former Address, if Changed Since Last Report)

Registrant’s telephone number, including area code: +972-4-988-9488

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
   

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 26, 2007, the Board of Directors of Protalix BioTherapeutics, Inc. (the “Company”) appointed Ms. Yodfat Harel Gross as a director of the Company. The appointment was made in accordance with Article V, Section 2 of the ByLaws of the Company. Ms. Harel Gross was appointed to serve as a director until the Company’s next annual meeting of shareholders and was appointed to serve on the Board of Director’s Audit Committee and Compensation Committee.

Item 8.01. Other Events

On June 26, 2007, the Company issued a press release announcing that its shares have been added to the broad market Russell 3000(R) Index. The press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(d)   Exhibits

99.1   Press release dated June 26, 2007.


 
  2 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  PROTALIX BIOTHERAPEUTICS, INC.
     
Date: June 27, 2007 By: /s/ David Aviezer
  Name:
Title: 		David Aviezer, Ph.D.
President and
Chief Executive Officer

 
  3